Redeye makes mixed estimate revisions on the back of Nekkar’s H1’24 report that beat our EPS forecas...
Weak Q2 margin of 5.0% (7.3%), but book-to-bill improved to 0.
Prostatype Genomics har nyligen lanserat sitt test Prostatype® på den viktiga amerikanska marknaden ...
Market headwinds continued in Q2 We lower 2025e EBIT on slower recovery in activity Easy comps in '2...
Redeye leaves a comment relating to the announcement of Werfen and its new POC system GEM Premier 70...
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H1 report.
The independent Data Monitoring Committee (DMC) recommends to proceed the clinical Tumorad-01, with ...
Loihde’s Q2 was better than anticipated. Net sales grew a modest 3% to EUR 35.
At the end of September Beyond Frames internal studio will release “Escaping Wonderland” based on “A...
Redeye concludes that Q2 revenues were weaker than expected, derived from short-term delays and orde...
5% org. sales growth, 7% adj. EBITA growth, neg. cash flow '24e-'26e adj.
Devport levererade en omsättning och resultat för det andra kvartalet i nivå med marknadens förväntn...
Q2: sales SEK 43m +30% y-o-y, adj. EBIT margin 28% (23%) Raise both '24e-'26e sales and EBIT by 7-5%...
Mangold uppdaterar cybersäkerhetsbolaget Cyber Security 1 (”CYBER1”).
Redeye updates its estimates and valuation after Navigo’s Q2 2024 report.
